Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis

By sjmartinez • June 20, 2024

Armstrong AW, Alexis AF, Blauvelt A, Silverberg JI, Feeney C, Levenberg M, Chan G, Zhang F, Fostvedt L. Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). 2024 Jun 19. doi: 10.1007/s13555-024-01183-3. Epub ahead of print. PMID: 38896380.

Tags: Dermatology, Publications

Chronic Urticaria Is Independently Associated with Atherosclerotic Cardiovascular Disease: A National Cohort Study of the MarketScan Databases

Cortes JA, Nong Y, Smart K, Aflatooni S, Palma G, Johnsen N, Ure A, Armstrong AW. Chronic Urticaria Is Independently Associated with Atherosclerotic Cardiovascular Disease:[...]

Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis

Armstrong AW, Burne R, Bin Sawad A, Lemyre A, Gauthier-Loiselle M, Guerin A, Vinson T, Milovac B, Balu S. Treatment Patterns and Economic Burden in[...]

DNA methylation profiles at hospital admission are associated with subsequent severe COVID-19 outcomes

Hsu FM, Pickering H, Bosinger SE, Eckalbar W, Maecker HT, Kim-Schulze S, Ozonoff A, Diray-Arce J, Schaenman JM, Reed EF, Pellegrini M. DNA methylation profiles[...]